Research programme: antibody drug conjugates - AbCellera/Prelude Therapeutics
Latest Information Update: 22 Dec 2023
At a glance
- Originator Abcellera; Prelude Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action SMARCA2 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer